- freely available
Therapeutic Targeting of Hyaluronan in the Tumor Stroma
AbstractThe tumor stroma, consisting of non-malignant cells and the extracellular matrix, undergoes significant quantitative and qualitative changes throughout malignant transformation and tumor progression. With increasing recognition of the role of the tumor microenvironment in disease progression, stromal components of the tumor have become attractive targets for therapeutic intervention. Stromal accumulation of the glycosaminoglycan hyaluronan occurs in many tumor types and is frequently associated with a negative disease prognosis. Hyaluronan interacts with other extracellular molecules as well as cellular receptors to form a complex interaction network influencing physicochemical properties, signal transduction, and biological behavior of cancer cells. In preclinical animal models, enzymatic removal of hyaluronan is associated with remodeling of the tumor stroma, reduction of tumor interstitial fluid pressure, expansion of tumor blood vessels and facilitated delivery of chemotherapy. This leads to inhibition of tumor growth and increased survival. Current evidence shows that abnormal accumulation of hyaluronan may be an important stromal target for cancer therapy. In this review we highlight the role of hyaluronan and hyaluronan-mediated interactions in cancer, and discuss historical and recent data on hyaluronidase-based therapies and the effect of hyaluronan removal on tumor growth.
Share & Cite This Article
Kultti, A.; Li, X.; Jiang, P.; Thompson, C.B.; Frost, G.I.; Shepard, H.M. Therapeutic Targeting of Hyaluronan in the Tumor Stroma. Cancers 2012, 4, 873-903.View more citation formats
Kultti A, Li X, Jiang P, Thompson CB, Frost GI, Shepard HM. Therapeutic Targeting of Hyaluronan in the Tumor Stroma. Cancers. 2012; 4(3):873-903.Chicago/Turabian Style
Kultti, Anne; Li, Xiaoming; Jiang, Ping; Thompson, Curtis B.; Frost, Gregory I.; Shepard, H. Michael. 2012. "Therapeutic Targeting of Hyaluronan in the Tumor Stroma." Cancers 4, no. 3: 873-903.